NEW YORK – BridgeBio Pharma subsidiary QED Therapeutics said on Wednesday that the US Food and Drug Administration accepted its new drug application for infigratinib to treat patients with FGFR-altered bile duct cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.